BOSTON, July 17 (Reuters) - Myriad Genetics Inc. (MYGN.O: Quote, Profile, Research), a maker of genetic tests to detect the risk of certain cancers, said on Monday that its experimental Alzheimer’s disease drug showed promise in a mid-stage trial. Data from a 12-month study showed that the drug, Flurizan, reduced the number of psychiatric episodes such as aggression and depression that can cause patients to be put into nursing homes.
